Wall Street analysts predict a 93.92% upside in Maze Therapeutics, Inc. (MAZE): Here's what you should know
Shares of Maze Therapeutics, Inc. (MAZE) have gained 22% over the past four weeks to close the last trading session at $32.25 ...
Model output · Signal date 2026-11-06
Maze Therapeutics, Inc. (MAZE) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 4891 stocks scored
Rank correlation · 90D
-46.0%
Spearman, 214 dates
Market Cap
$1.81B
small-cap · #38 of 60 peers
Summary
Maze Therapeutics, Inc. (MAZE) stock forecast summary
Our AI scores Maze Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Maze Therapeutics, Inc. is a small-cap company with a market capitalization of $1.81B. It ranks number 38 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For MAZE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -46.0%, measured on 214 forecast dates between 2025-05-16 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -22.0%, measured on 257 forecast dates between 2025-05-16 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MAZE included.
Price
MAZE price chart and AI forecast
Cross-section · 2026-10-30
How MAZE ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Maze Therapeutics, Inc. (MAZE) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | MAZE | Rank |
|---|---|---|
| Market Cap | $1.81B | 38/60 |
| P/B Ratio | 3.99x | 28/48 |
| EPS | $-1.89 | – |
| Book Value/Share | $8.16 | – |
| FCF/Share | $-1.92 | – |
Profitability & Margins
| Metric | MAZE | Rank |
|---|---|---|
| ROE | -29.5% | 20/44 |
| ROA | -25.1% | 26/47 |
| ROIC | -28.6% | 26/52 |
| Operating Margin | -364.0% | 30/41 |
| Net Margin | -334.0% | 26/36 |
| EBT Margin | -281.7% | 30/43 |
Financial Health
| Metric | MAZE | Rank |
|---|---|---|
| Current Ratio | 18.31x | 3/59 |
| D/E Ratio | 0.17x | 41/52 |
| Financial Leverage | 1.17x | 40/51 |
| Working Capital | $397M | 33/58 |
Cash Flow
| Metric | MAZE | Rank |
|---|---|---|
| Operating Cash Flow | -$107M | 25/56 |
| Free Cash Flow | -$107M | 24/49 |
| Capital Spending | -$300K | 6/49 |
Income Statement
| Metric | MAZE | Rank |
|---|---|---|
| Operating Income | -$146M | 23/53 |
| Net Income | -$134M | 20/47 |
| R&D Expense | $122M | 42/55 |
Dividend & Shareholder Information
| Metric | MAZE | Rank |
|---|---|---|
| Shares Outstanding | 56M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $420M | 79.1% of assets |
| Cash & Short-term Investments | $203M | 38.1% of assets |
| Total Liabilities | $78M | 14.8% of assets |
| Short-term Debt | $21M | 3.9% of assets |
Quarterly Financial Reports
MAZE quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Maze Therapeutics, Inc. (MAZE) industry peers
Companies classified under the same SEC industry code as Maze Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MAZE Maze Therapeutics, Inc. | $1.81B | |
| AMGN Amgen Inc | $248.84B | |
| GILD Gilead Sciences, Inc. | $207.84B | |
| MRNA Moderna, Inc. | $96.40B | |
| ARGX Argenx Se | $55.37B | |
| RVMD Revolution Medicines, Inc. | $42.80B | |
| BIIB Biogen Inc. | $36.06B | |
| BNTX Biontech Se | $21.71B | |
| EXEL Exelixis, Inc. | $16.77B | |
| NBIX Neurocrine Biosciences Inc | $16.24B | |
| HALO Halozyme Therapeutics, Inc. | $13.96B | |
| TECH Bio-Techne Corp | $11.41B | |
| QGEN Qiagen N.V. | $11.03B | |
| KYMR Kymera Therapeutics, Inc. | $10.94B | |
| RGEN Repligen Corp | $10.77B | |
| PCVX Vaxcyte, Inc. | $9.21B | |
| KRYS Krystal Biotech, Inc. | $8.90B | |
| IBRX Immunitybio, Inc. | $8.49B | |
| TWST Twist Bioscience Corp | $7.56B | |
| IMVT Immunovant, Inc. | $5.86B | |
| CGON Cg Oncology, Inc. | $5.74B | |
| KOD Kodiak Sciences Inc. | $5.72B | |
| SRRK Scholar Rock Holding Corp | $5.54B | |
| CRSP Crispr Therapeutics Ag | $4.70B | |
| ADPT Adaptive Biotechnologies Corp | $4.28B | |
| RLAY Relay Therapeutics, Inc. | $3.95B | |
| IOVA Iovance Biotherapeutics, Inc. | $3.51B | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | |
| DNLI Denali Therapeutics Inc. | $3.15B | |
| ADMA Adma Biologics, Inc. | $2.96B | |
| BEAM Beam Therapeutics Inc. | $2.67B | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.13B | |
| VCEL Vericel Corp | $2.10B | |
| LIFE Atyr Pharma Inc | $2.08B | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.08B | |
| REPL Replimune Group, Inc. | $1.96B | |
| BCRX Biocryst Pharmaceuticals Inc | $1.95B | |
| VIR Vir Biotechnology, Inc. | $1.86B | |
| MESO Mesoblast Ltd | $1.81B | |
| ALVO Alvotech | $1.62B | |
| NVAX Novavax Inc | $1.61B | |
| IMCR Immunocore Holdings Plc | $1.46B | |
| TSHA Taysha Gene Therapies, Inc. | $1.33B | |
| VOR Vor Biopharma Inc. | $1.15B | |
| CGEM Cullinan Therapeutics, Inc. | $1.01B | |
| ODTX Odyssey Therapeutics, Inc. | $907M | |
| GLUE Monte Rosa Therapeutics, Inc. | $874M | |
| IMTX Immatics N.V. | $829M | |
| MGTX Meiragtx Holdings Plc | $817M | |
| PRME Prime Medicine, Inc. | $799M | |
| SANA Sana Biotechnology, Inc. | $700M | |
| SLDB Solid Biosciences Inc. | $699M | |
| SLBT Sl Science Holding Ltd | $679M | |
| DNA Ginkgo Bioworks Holdings, Inc. | $671M | |
| AURA Aura Biosciences, Inc. | $657M | |
| FDMT 4d Molecular Therapeutics, Inc. | $621M | |
| DBVT Dbv Technologies S.A. | $616M | |
| CADL Candel Therapeutics, Inc. | $615M | |
| VALN Valneva Se | $551M | |
| ENTX Entera Bio Ltd. | $518M |
Where MAZE sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Maze Therapeutics, Inc. (MAZE) stock news
What makes Maze Therapeutics, Inc. (MAZE) a new buy stock
Investors might want to bet on Maze Therapeutics, Inc. (MAZE), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Yes. Welcome to Day 2 of Citi's Back to School Biopharma Conference. I'm Eric Joseph, Senior Biotech Analyst with the firm. And our session now is with Maze Therapeutics. It's my pleasure to have with ...
FAQ
Maze Therapeutics, Inc. (MAZE) stock forecast FAQ
What is the Maze Therapeutics, Inc. (MAZE) stock forecast?
Our AI scores Maze Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Maze Therapeutics, Inc. stock predictions?
For MAZE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -46.0%, measured on 214 forecast dates between 2025-05-16 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -22.0%, measured on 257 forecast dates between 2025-05-16 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Maze Therapeutics, Inc. forecasts updated?
Maze Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Maze Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, MAZE included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.